Alcon (ALC) is up about 3% in today’s session, with the clearest near-term catalyst being improving analyst sentiment around its 2026 growth setup. A recent Wall Street upgrade to Overweight (from Equal Weight) paired with a higher price target ($97 from $88) emphasized that newer product launches are gaining traction and could support upside to Alcon’s 2026 guidance framework.

The upgrade piggybacks on Alcon’s late-February results and commentary, which showed strong topline momentum: fourth-quarter 2025 sales were about $2.7 billion, up 9% reported (about 7% excluding FX). Management framed the outlook around continued demand in eye care and contributions from newer launches—keeping investors focused on mix and innovation rather than near-term noise.

Near-term attention shifts to Alcon’s annual general meeting on April 30, 2026, and the next earnings report window (widely anticipated in early May). Separately, investors continue to digest the March 16, 2026 termination of Alcon’s LENSAR transaction after regulatory headwinds; while that deal is off the table, today’s tape suggests the market is refocusing on organic execution and product-cycle strength.